1087 related articles for article (PubMed ID: 9002762)
1. Clinical relevance of 111In-octreotide scans in CNS tumors.
Sciuto R; Ferraironi A; Semprebene A; Occhipinti E; Mastrostefano R; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):101-3. PubMed ID: 9002762
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging in CNS tumours using 111In-octreotide.
Maini CL; Sciuto R; Tofani A; Ferraironi A; Carapella CM; Occhipinti E; Mottolese M; Crecco M
Nucl Med Commun; 1995 Sep; 16(9):756-66. PubMed ID: 7478408
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
4. 111In-octreotide scintigraphy in small cell lung cancer.
Semprebene A; Ferraironi A; Franciotti G; Venturo I; Giunta S; Lopez M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
6. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors in meningiomas: a scintigraphic study using 111In-DTPA-D-Phe-1-octreotide.
Maini CL; Tofani A; Sciuto R; Carapella C; Cioffi R; Crecco M
Nucl Med Commun; 1993 Jul; 14(7):550-8. PubMed ID: 8355914
[TBL] [Abstract][Full Text] [Related]
8. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
9. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
10. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
[TBL] [Abstract][Full Text] [Related]
12. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
13. Indium-111 octreotide scintigraphy in neurofibromatosis.
Maini CL; Cioffi RP; Tofani A; Sciuto R; Fontana M; Carapella CM; Crecco M
Eur J Nucl Med; 1995 Mar; 22(3):201-6. PubMed ID: 7789392
[TBL] [Abstract][Full Text] [Related]
14. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
[TBL] [Abstract][Full Text] [Related]
15. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive differentiation of meningiomas from other brain tumours using combined 111Indium-octreotide/99mtechnetium-DTPA brain scintigraphy.
Barth A; Haldemann AR; Reubi JC; Godoy N; Rösler H; Kinser JA; Seiler RW
Acta Neurochir (Wien); 1996; 138(10):1179-85. PubMed ID: 8955437
[TBL] [Abstract][Full Text] [Related]
17. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy.
Bombardieri E; Crippa F; Cataldo I; Chiti A; Seregni E; Soresi E; Boffi R; Invernizzi G; Buraggi GL
Eur J Cancer; 1995; 31A(2):184-8. PubMed ID: 7718323
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
20. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
